300639 Stock Overview
Engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Guangdong Hybribio Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.24 |
| 52 Week High | CN¥10.08 |
| 52 Week Low | CN¥4.32 |
| Beta | 0.42 |
| 11 Month Change | -7.26% |
| 3 Month Change | 10.55% |
| 1 Year Change | -45.92% |
| 33 Year Change | -62.85% |
| 5 Year Change | -23.59% |
| Change since IPO | 33.72% |
Recent News & Updates
Shareholder Returns
| 300639 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.4% | -0.4% | 1.1% |
| 1Y | -45.9% | -29.0% | -20.4% |
Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -29% over the past year.
Return vs Market: 300639 underperformed the CN Market which returned -20.4% over the past year.
Price Volatility
| 300639 volatility | |
|---|---|
| 300639 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.5% |
| 10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 300639's share price has been volatile over the past 3 months.
Volatility Over Time: 300639's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,669 | Jianyu Wang | www.hybribio.cn |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary
| 300639 fundamental statistics | |
|---|---|
| Market cap | CN¥3.36b |
| Earnings (TTM) | -CN¥59.30m |
| Revenue (TTM) | CN¥906.70m |
3.7x
P/S Ratio-56.7x
P/E RatioIs 300639 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300639 income statement (TTM) | |
|---|---|
| Revenue | CN¥906.70m |
| Cost of Revenue | CN¥437.10m |
| Gross Profit | CN¥469.61m |
| Other Expenses | CN¥528.91m |
| Earnings | -CN¥59.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.092 |
| Gross Margin | 51.79% |
| Net Profit Margin | -6.54% |
| Debt/Equity Ratio | 1.1% |
How did 300639 perform over the long term?
See historical performance and comparison